LABORATORY CORPORATION OF AMERICA HOLDINGS (NYSE:LH) Files An 8-K Submission of Matters to a Vote of Security Holders

0

LABORATORY CORPORATION OF AMERICA HOLDINGS (NYSE:LH) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07

Submission of Matters to a Vote of Security
Holders.

The 2017 Annual Meeting of Shareholders (the Annual Meeting) of
Laboratory Corporation of America Holdings (the Company) was held
on May11, 2017. As of March14, 2017, the date of record for
determining the Companys shareholders entitled to vote on the
proposals presented at the Annual Meeting, there were 102,429,958
shares of the Companys common stock issued and outstanding and
entitled to vote at the Annual Meeting. The holders of 89,991,351
shares of the Companys issued and outstanding common stock were
represented in person or by proxy at the Annual Meeting,
constituting a quorum. The proposals presented at the Annual
Meeting are described in detail in the Companysdefinitive
proxystatement filed with the Securities and Exchange Commission
on March31, 2017. The vote results detailed below represent final
results as certified by the Inspector of Elections.

Proposal 1.

The Companys shareholders elected the following persons, who were
listed in the Proxy Statement, to the Companys Board of Directors
to hold office for the term expiring at the 2018 Annual Meeting
of Shareholders or until their successors are elected and
qualified or until their earlier death, resignation or removal:

Votes For Votes Against Abstentions Broker Non-Votes

David P. King

77,546,888 4,701,594 413,380 7,329,489

Kerrii B. Anderson

81,708,902 923,700 29,260 7,329,489

Jean-Luc Blingard

64,731,624 17,858,623 71,615 7,329,489

D. Gary Gilliland, M.D., Ph.D.

82,350,059 281,818 29,985 7,329,489

Garheng Kong, M.D., Ph.D.

71,868,102 10,763,654 30,106 7,329,489

Robert E. Mittelstaedt, Jr.

81,033,295 1,597,802 30,765 7,329,489

Peter M. Neupert

81,913,309 718,296 30,257 7,329,489

Richelle P. Parham

82,357,757 272,701 31,404 7,329,489

Adam H. Schechter

82,448,661 181,090 32,111 7,329,489

R. Sanders Williams, M.D.

82,037,129 594,340 30,393 7,329,489

Proposal 2.

The Companys shareholders approved, in an advisory (non-binding)
vote, the compensation of the Companys named executive officers.
The votes regarding this proposal were as follows:

Votes For

Votes Against

Abstentions

Broker Non-Votes

77,351,882 5,124,358 185,622 7,329,489

Proposal 3.

The Companys shareholders voted, on an advisory (non-binding)
basis, on the frequency of future advisory shareholder votes on
the compensation of the Companys named executive officers.The
votes regarding this proposal were as follows:

1 Year

2 Years

3 Years

Abstentions

72,940,471 347,485 9,305,092 68,814

In accordance with the results for Proposal 3, the Companys Board
of Directors has determined that future advisory votes on the
compensation of the Companys named executive officers will be
held every year.Thus, the next shareholder advisory vote on the
compensation of the Companys named executive officers will be
held at the Companys 2018 Annual Meeting of Shareholders.

Proposal 4.

The Companys shareholders ratified the appointment of
PricewaterhouseCoopers LLP as the Companys independent registered
public accounting firm for the fiscal year ending December31,
2017. The votes regarding this proposal were as follows:

Votes For

Votes Against

Abstentions

Broker Non-Votes

87,707,685 2,243,242 40,424

Proposal 5.

The Companys shareholders did not approve the shareholder
proposal described in the Proxy Statement. The votes regarding
this proposal were as follows:

Votes For

Votes Against

Abstentions

Broker Non-Votes

3,226,088 76,501,212 2,934,562 7,329,489


About LABORATORY CORPORATION OF AMERICA HOLDINGS (NYSE:LH)

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The LCD segment is an independent clinical laboratory business, which offers menu of frequently requested and specialty testing through an integrated network of primary and specialty laboratories across the United States. The CDD segment offers drug development services, and provides a range of drug research and development (R&D) and market access services to biopharmaceutical companies and medical device companies across the world. It serves a range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers.

LABORATORY CORPORATION OF AMERICA HOLDINGS (NYSE:LH) Recent Trading Information

LABORATORY CORPORATION OF AMERICA HOLDINGS (NYSE:LH) closed its last trading session down -0.63 at 137.51 with 750,506 shares trading hands.